We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01403467
First Posted: July 27, 2011
Last Update Posted: July 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ramathibodi Hospital
  Purpose
This current study aimed to demonstrate the effectiveness of the addition of CPAP to the current conventional therapy in terms of airway obstruction improvement in acute asthma patients.

Condition Intervention Phase
Acute Asthma Device: Continuous positive airway pressure Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation

Further study details as provided by Ramathibodi Hospital:

Primary Outcome Measures:
  • an improvement in PEFR, as % predicted [ Time Frame: 75 mins ]

Enrollment: 86
Study Start Date: April 2009
Study Completion Date: January 2011
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NIPPV Device: Continuous positive airway pressure
CPAP 8 cmH2O
Other Name: GoodKnight 420 G; Nellcor Puritan Bennett Inc.

Detailed Description:
Continuous positive airway pressure (CPAP) is widely used in providing ventilator support. However, its role in an acute asthmatic attack is uncertain. The purpose of this study was to compare the efficacy of CPAP when used in addition to conventional therapy with conventional therapy alone in the management of acute asthma exacerbation.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • aged over 18 years
  • known asthmatic patients visiting ED with acute exacerbation
  • had given their written informed consent.

Exclusion Criteria:

  • smoking history
  • chronic obstructive pulmonary disease
  • required intubation
  • instability of hemodynamic or arrhythmia
  • unable to perform PEFR
  • facial abnormality
  • pulmonary infiltration
  • pregnancy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01403467


Locations
Thailand
Ramathibodi Hospital
Bangkok, Thailand, 10400
Sponsors and Collaborators
Ramathibodi Hospital
Investigators
Principal Investigator: Yuda Sutherasan, M.D. Ramathibodi Hospital, Mahidol University
  More Information

Responsible Party: Dr.Yuda Sutherasan, Ramathibodi Hospital
ClinicalTrials.gov Identifier: NCT01403467     History of Changes
Other Study ID Numbers: 02-52-28
MURA2009/1239 ( Other Identifier: Ramathibodi Hospital )
First Submitted: July 25, 2011
First Posted: July 27, 2011
Last Update Posted: July 27, 2011
Last Verified: December 2010

Keywords provided by Ramathibodi Hospital:
Bronchial disease
asthma
continuous positive airway pressure (CPAP)
Bronchoconstriction

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases